STOCK TITAN

Athira Pharma to Participate in Upcoming May Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Summary: Athira Pharma, Inc. (NASDAQ: ATHA) will be participating in the Sidoti May 2024 Virtual Investor Conference and The Citizens JMP Life Sciences Conference in May. The Company management will present at these conferences to discuss their focus on developing small molecules to restore neuronal health and slow neurodegeneration. Live webcasts and archived replays will be available on the Athira website.

Positive
  • None.
Negative
  • None.

BOTHELL, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that Company management will participate in the following upcoming investor conferences in May.

Sidoti May 2024 Virtual Investor Conference
Format: Company Presentation
Date and Time: Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET
Location: Virtual

The Citizens JMP Life Sciences Conference
Format: Fireside Chat
Date and Time: Monday, May 13, 2024, from 1:30 p.m. - 1:55 p.m. ET
Location: New York Hilton Midtown

Live webcasts of the panel and presentations can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor. An archived replay of the webcasts will be available for at least 30 days following the event.

About Athira Pharma, Inc.
Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of therapeutic candidates that modulate the neurotrophic HGF system, including fosgonimeton, which is being evaluated for the potential treatment of mild-to-moderate Alzheimer’s disease in the Phase 2/3 LIFT-AD trial that is expected to report topline data in the second half of 2024. For more information, visit www.athira.com. You can also follow Athira on FacebookLinkedIn and @athirapharma on X, (formerly known as Twitter), and Instagram.

Investor Contacts:
Julie Rathbun
Athira Pharma
Julie.rathbun@athira.com
206-769-9219

Anne Marie Fields
Stern Investor Relations
annemarie.fields@sternir.com
332-213-1956

Media Contact:
Janine Bogris
Inizio Evoke Comms
Janine.bogris@inizioevoke.com
201-245-6838


FAQ

When will Athira Pharma participate in the Sidoti May 2024 Virtual Investor Conference?

Athira Pharma will participate in the Sidoti May 2024 Virtual Investor Conference on Wednesday, May 8, 2024, from 10:45 a.m. - 11:15 a.m. ET.

What is the focus of Athira Pharma as a biopharmaceutical company?

Athira Pharma focuses on developing small molecules to restore neuronal health and slow neurodegeneration.

Where can the live webcasts of the conferences be accessed?

The live webcasts of the conferences can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations-investor.

Athira Pharma, Inc.

NASDAQ:ATHA

ATHA Rankings

ATHA Latest News

ATHA Stock Data

21.60M
38.44M
2.37%
63.76%
2.57%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States of America
BOTHELL